VC
RNTX

Voss Capital’s Rein Therapeutics RNTX Stock Holding History

Voss Capital’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.7M Buy
4,388,362
+144,393
+3% +$179K 0.3% 35
2025
Q4 		$4.92M Buy
4,243,969
+1,577,437
+59% +$2.17M 0.24% 39
2025
Q3 		$3.05M Buy
2,666,532
+1,232,846
+86% +$1.57M 0.15% 42
2025
Q2 		$2.01M Buy
1,433,686
+442,970
+45% +$798K 0.14% 41
2025
Q1 		$1.75M Buy
990,716
+34,521
+4% +$72.4K 0.13% 44
2024
Q4 		$2.2M Buy
+956,195
New +$2.9M 0.16% 40

Other funds holding RNTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Voss Capital's RNTX Position: Q1 2026 in Review

Voss Capital increased its Rein Therapeutics (RNTX) stake by 3.4% in Q1 2026, buying an estimated $179K and bringing the position to 4,388,362 shares worth $5.7M. The position accounts for 0.3% of the portfolio, ranked #35.

Voss Capital first reported a position in RNTX in Q4 2024 and has held it in 6 quarters since. 46 funds tracked by Wall St. Rank hold RNTX as of Q1 2026.

  • Voss Capital held 4,388,362 shares of Rein Therapeutics worth $5.7M as of Q1 2026.
  • Voss Capital bought 144,393 Rein Therapeutics shares in Q1 2026, an estimated $179K.
  • Rein Therapeutics made up 0.3% of Voss Capital's portfolio in Q1 2026, its #35 holding.
  • Voss Capital first reported a position in Rein Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 46 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2026.

Based on Voss Capital's 13F filing for Q1 2026, filed 15 May 2026.